Additionally, the 36-month beta value for CRSP is 1.74. There are mixed opinions on the stock, with 12 analysts rating it as a “buy,” 5 rating it as “overweight,” 10 rating it as “hold,” and 1 rating it as “sell.”
The public float for CRSP is 82.79M and currently, short sellers hold a 25.44% ratio of that float. The average trading volume of CRSP on June 05, 2025 was 2.03M shares.
CRSP) stock’s latest price update
CRISPR Therapeutics AG (NASDAQ: CRSP)’s stock price has soared by 0.03 in relation to previous closing price of 38.04. Nevertheless, the company has seen a gain of 2.22% in its stock price over the last five trading days. zacks.com reported 2025-06-04 that CRSP aims to extend its gene-editing lead with in vivo candidates after Casgevy’s ex vivo breakthrough success.
CRSP’s Market Performance
CRSP’s stock has risen by 2.22% in the past week, with a monthly rise of 1.14% and a quarterly drop of -13.21%. The volatility ratio for the week is 1.88% while the volatility levels for the last 30 days are 3.17% for CRISPR Therapeutics AG The simple moving average for the last 20 days is 2.60% for CRSP’s stock, with a simple moving average of -12.41% for the last 200 days.
Analysts’ Opinion of CRSP
Many brokerage firms have already submitted their reports for CRSP stocks, with Evercore ISI repeating the rating for CRSP by listing it as a “Outperform.” The predicted price for CRSP in the upcoming period, according to Evercore ISI is $99 based on the research report published on February 14, 2025 of the current year 2025.
TD Cowen, on the other hand, stated in their research note that they expect to see CRSP reach a price target of $35. The rating they have provided for CRSP stocks is “Hold” according to the report published on February 12th, 2025.
H.C. Wainwright gave a rating of “Buy” to CRSP, setting the target price at $65 in the report published on February 03rd of the current year.
CRSP Trading at 3.25% from the 50-Day Moving Average
After a stumble in the market that brought CRSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.95% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRSP starting from Patel Naimish, who sale 3,932 shares at the price of $35.94 back on May 29 ’25. After this action, Patel Naimish now owns 6,068 shares of CRISPR Therapeutics AG, valued at $141,316 using the latest closing price.
Kulkarni Samarth, the Chief Executive Officer of CRISPR Therapeutics AG, sale 10,031 shares at $41.23 during a trade that took place back on Mar 21 ’25, which means that Kulkarni Samarth is holding 195,085 shares at $413,578 based on the most recent closing price.
Stock Fundamentals for CRSP
Current profitability levels for the company are sitting at:
- -13.13 for the present operating margin
- -2.59 for the gross margin
The net margin for CRISPR Therapeutics AG stands at -10.68. The total capital return value is set at -0.23. Equity return is now at value -19.71, with -16.75 for asset returns.
Based on CRISPR Therapeutics AG (CRSP), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -1.4.
Currently, EBITDA for the company is -447.31 million with net debt to EBITDA at 0.03. When we switch over and look at the enterprise to sales, we see a ratio of 90.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.64.
Conclusion
In conclusion, CRISPR Therapeutics AG (CRSP) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high..
